Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors

Autotaxin (ATX) is a secreted glycoprotein, widely present in biological fluids, largely responsible for extracellular lysophosphatidic acid (LPA) production. LPA is a bioactive growth-factor-like lysophospholipid that exerts pleiotropic effects in almost all cell types, exerted through at least six...

Full description

Bibliographic Details
Main Authors: Christiana Magkrioti, Eleanna Kaffe, Elli-Anna Stylianaki, Camelia Sidahmet, Georgia Melagraki, Antreas Afantitis, Alexios N. Matralis, Vassilis Aidinis
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/21/19/7002
id doaj-f5419fcd5bbf4b3cb910b5a4115476ee
record_format Article
spelling doaj-f5419fcd5bbf4b3cb910b5a4115476ee2020-11-25T03:22:17ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-09-01217002700210.3390/ijms21197002Structure-Based Discovery of Novel Chemical Classes of Autotaxin InhibitorsChristiana Magkrioti0Eleanna Kaffe1Elli-Anna Stylianaki2Camelia Sidahmet3Georgia Melagraki4Antreas Afantitis5Alexios N. Matralis6Vassilis Aidinis7Institute for Bioinnovation, Biomedical Sciences Research Center Alexander Fleming, Fleming 34, 16672 Athens, GreeceInstitute for Bioinnovation, Biomedical Sciences Research Center Alexander Fleming, Fleming 34, 16672 Athens, GreeceInstitute for Bioinnovation, Biomedical Sciences Research Center Alexander Fleming, Fleming 34, 16672 Athens, GreeceInstitute for Bioinnovation, Biomedical Sciences Research Center Alexander Fleming, Fleming 34, 16672 Athens, GreeceNovaMechanics Ltd, Princess De Tyras 16, 1065 Nicosia, CyprusNovaMechanics Ltd, Princess De Tyras 16, 1065 Nicosia, CyprusInstitute for Bioinnovation, Biomedical Sciences Research Center Alexander Fleming, Fleming 34, 16672 Athens, GreeceInstitute for Bioinnovation, Biomedical Sciences Research Center Alexander Fleming, Fleming 34, 16672 Athens, GreeceAutotaxin (ATX) is a secreted glycoprotein, widely present in biological fluids, largely responsible for extracellular lysophosphatidic acid (LPA) production. LPA is a bioactive growth-factor-like lysophospholipid that exerts pleiotropic effects in almost all cell types, exerted through at least six G-protein-coupled receptors (LPAR1-6). Increased ATX expression has been detected in different chronic inflammatory diseases, while genetic or pharmacological studies have established ATX as a promising therapeutic target, exemplified by the ongoing phase III clinical trial for idiopathic pulmonary fibrosis. In this report, we employed an in silico drug discovery workflow, aiming at the identification of structurally novel series of ATX inhibitors that would be amenable to further optimization. Towards this end, a virtual screening protocol was applied involving the search into molecular databases for new small molecules potentially binding to ATX. The crystal structure of ATX in complex with a known inhibitor (HA-155) was used as a molecular model docking reference, yielding a priority list of 30 small molecule ATX inhibitors, validated by a well-established enzymatic assay of ATX activity. The two most potent, novel and structurally different compounds were further structurally optimized by deploying further in silico tools, resulting to the overall identification of six new ATX inhibitors that belong to distinct chemical classes than existing inhibitors, expanding the arsenal of chemical scaffolds and allowing further rational design.https://www.mdpi.com/1422-0067/21/19/7002atotaxinsmall moleculesATX inhibitorsin silico screening
collection DOAJ
language English
format Article
sources DOAJ
author Christiana Magkrioti
Eleanna Kaffe
Elli-Anna Stylianaki
Camelia Sidahmet
Georgia Melagraki
Antreas Afantitis
Alexios N. Matralis
Vassilis Aidinis
spellingShingle Christiana Magkrioti
Eleanna Kaffe
Elli-Anna Stylianaki
Camelia Sidahmet
Georgia Melagraki
Antreas Afantitis
Alexios N. Matralis
Vassilis Aidinis
Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors
International Journal of Molecular Sciences
atotaxin
small molecules
ATX inhibitors
in silico screening
author_facet Christiana Magkrioti
Eleanna Kaffe
Elli-Anna Stylianaki
Camelia Sidahmet
Georgia Melagraki
Antreas Afantitis
Alexios N. Matralis
Vassilis Aidinis
author_sort Christiana Magkrioti
title Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors
title_short Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors
title_full Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors
title_fullStr Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors
title_full_unstemmed Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors
title_sort structure-based discovery of novel chemical classes of autotaxin inhibitors
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2020-09-01
description Autotaxin (ATX) is a secreted glycoprotein, widely present in biological fluids, largely responsible for extracellular lysophosphatidic acid (LPA) production. LPA is a bioactive growth-factor-like lysophospholipid that exerts pleiotropic effects in almost all cell types, exerted through at least six G-protein-coupled receptors (LPAR1-6). Increased ATX expression has been detected in different chronic inflammatory diseases, while genetic or pharmacological studies have established ATX as a promising therapeutic target, exemplified by the ongoing phase III clinical trial for idiopathic pulmonary fibrosis. In this report, we employed an in silico drug discovery workflow, aiming at the identification of structurally novel series of ATX inhibitors that would be amenable to further optimization. Towards this end, a virtual screening protocol was applied involving the search into molecular databases for new small molecules potentially binding to ATX. The crystal structure of ATX in complex with a known inhibitor (HA-155) was used as a molecular model docking reference, yielding a priority list of 30 small molecule ATX inhibitors, validated by a well-established enzymatic assay of ATX activity. The two most potent, novel and structurally different compounds were further structurally optimized by deploying further in silico tools, resulting to the overall identification of six new ATX inhibitors that belong to distinct chemical classes than existing inhibitors, expanding the arsenal of chemical scaffolds and allowing further rational design.
topic atotaxin
small molecules
ATX inhibitors
in silico screening
url https://www.mdpi.com/1422-0067/21/19/7002
work_keys_str_mv AT christianamagkrioti structurebaseddiscoveryofnovelchemicalclassesofautotaxininhibitors
AT eleannakaffe structurebaseddiscoveryofnovelchemicalclassesofautotaxininhibitors
AT elliannastylianaki structurebaseddiscoveryofnovelchemicalclassesofautotaxininhibitors
AT cameliasidahmet structurebaseddiscoveryofnovelchemicalclassesofautotaxininhibitors
AT georgiamelagraki structurebaseddiscoveryofnovelchemicalclassesofautotaxininhibitors
AT antreasafantitis structurebaseddiscoveryofnovelchemicalclassesofautotaxininhibitors
AT alexiosnmatralis structurebaseddiscoveryofnovelchemicalclassesofautotaxininhibitors
AT vassilisaidinis structurebaseddiscoveryofnovelchemicalclassesofautotaxininhibitors
_version_ 1724610113619099648